Lancet Neurology

Article	Citations
Increasing diversity in dementia research	1765
The predictive value and clinical use of the neurological pupillary index – Authors' reply	1381
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	1351
Lessons and future directions for GBA1-targeting therapies	1136
Resolution of expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study	1004
Correction to Lancet Neurol 2025; 24: 850–65	715
Correction to Lancet Neurol 2024; 23: 168–77	682
Correction to Lancet Neurol 2021; 20: 448–59	618
Correction to Lancet Neurol 2020; 19: 391–401	605
Implications of the KIWE trial for low-income and lower-middle-income countries	588
Dementia diagnosis in the anti-amyloid era	514
RAB32 mutation in Parkinson's disease	492
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis	368
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	351
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	348
Multidisciplinary care for amyotrophic lateral sclerosis	339
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	337
The relevance of social and commercial determinants for neurological health	297
Correction to Lancet Neurol 2025; 24: 850–65	270
Adjunct dexamethasone in herpes simplex virus encephalitis	264
Anti-CD19 CAR T cells for refractory myasthenia gravis	261
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	257
Global burden of stroke: dynamic estimates to inform action	243
Traumatic brain injury research: homogenising heterogeneity	234
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	222

The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease	211
Surrogate endpoints for progressive multifocal leukoencephalopathy	209
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment	205
Diana Cejas	200
Parkinson's disease is a recognisable and useful diagnostic entity	200
Aspiring to restore arm and hand function after stroke	188
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	180
Albert Kwaku Akpalu	173
A chilly tale of dementia	168
A nasal CGRP receptor antagonist for acute migraine therapy	167
A study in healing the wounds of trauma	161
Trials in intracerebral haemorrhage: a path to success?	160
Delving into the human mind	158
Beyond the modular brain	149
Considering the neurological health needs of LGBTQIA people	146
A sensitive portrayal of a controversial condition	144
2025 for neuromuscular diseases: a year of multiple advances	142
Amyotrophic lateral sclerosis from genotoxins alone?	142
Guiding the future of neurology: our peer-reviewers in 2025	137
Global burden of headache disorders: innovations, disparities, and priorities for action	135
Correction to Lancet Neurol 2023; 22: 812–25	134
The prescription of valproate: risk of harm	134
Correction to Lancet Neurol 2022; 21: 284–94	133
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	130
Social connection: a fundamental need for good health	129
From stroke awareness to stroke action awareness	128
Gene therapy for X-linked myotubular myopathy: the challenges	125
Miratul Muqit: leading an alliance to decode Parkinson's disease	122
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	120
Deep brain stimulation for the treatment of patients with dystonia: advances towards network-based personalised care	120
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	117
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	111
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	107
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	106
Functional or hysterical?	103
α-synuclein seed amplification and its uses in Parkinson's disease	102
Global burden of meningitis: progress, gaps, and priorities	102
Diagnosis and pathogenesis of dystonia: clinical heterogeneity, shared mechanisms, and neurodevelopmental origins	101
Personalised neuromodulation in patients with dystonia	100
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	98
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	98
Multiple sclerosis in 2022: old players, new insights	98
Expansion of stenting indications in the USA	97
New results for risdiplam in spinal muscular atrophy	97
Responsible innovation in neurology	96
Exploring immunomodulation with azathioprine in Parkinson's disease	95
Jessica Ailani	95
Supporting young carers across neurological disorders	94
A proposal for equity neuroscience	94
Changing multiple-sclerosis-induced thoughts and behaviours	93

Thank you to The Lancet Neurology's peer reviewers in 2025	92
Learning to be an adult with a disability	92
Correction to Lancet Neurol 2024; 23: 110–22	89
Revisiting candesartan: new evidence for an old option in migraine prevention	88
Cognitive function in people with functional seizures	88
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis	87
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis – Authors’ reply	86
Major advances in Parkinson's disease over the past two decades and future research directions	84
Neurological infections in 2023: surveillance and prevention	82
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	82
Rethinking AI trials in brain health	82
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	81
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	81
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	79
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	79
Detection of awareness after brain injury: time for change	78
Improving thrombolysis efficiency for acute ischaemic stroke	78
ELEVATEd hope for patients after migraine treatment failure	76
Monitoring brainwaves while gallery visitors view artworks	75
Pragmatic solutions for the global burden of stroke	75
Neuroprotection in acute ischaemic stroke: reasons for optimism?	75
A call for optimal oral care in patients with ALS	75
Expanding the spectrum of type 1 IFN neuroinflammation	75
Eugenia Martínez	74
Headache research in 2023: advancing therapy and technology	72
Sleeping matters	71
Bastiaan Bloem: power against Parkinson's disease	70
Andrea Schneider	69
Consciousness contextualised	69
Living with dementia: seeing the world and adapting to it	69
Targeting auto-antibodies for CIDP: hope and questions	68
Thrombolysis before endovascular treatment of tandem lesions	67
Correction to Lancet Neurol 2024; 23: 961–62	66
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	64
Epilepsy research in 2022: clinical advances	63
The AfrAbia+plus Parkinson's Disease Genomic Consortium	63
Caution on the use of α2δ-ligands in neuropathic pain	63
Siddharth Srivastava	62
Questions about the brain at Edinburgh Festival Fringe	62
Highlights in traumatic brain injury research in 2024	61
Correction to Lancet Neurol 2024; 23: 344–81	61
Blocking inhibitors of axon growth after spinal cord injury	61
Neurorehabilitation as a cornerstone of recovery	59
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	59
Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023	57
Spontaneous spinal CSF leaks: a rare variant exome sequencing study and functional analysis	57
20 years of iPS cells	57
Clinical presentations and pathophysiological mechanisms of dystroglycanopathy: advancing therapeutic strategies	57
Bruton's tyrosine kinase inhibitors: a new class of multiple sclerosis therapeutics	57
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	56
Diagnosis and treatment of orthostatic hypotension	56
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	56
The global challenge of hypertension	55
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	55
The torment of needing to know for sure	55
Angela Dos Santos	54
Over a decade of MR-guided focused ultrasound	53
Correction to Lancet Neurol 2024; 23: 465–76	53
Therapies for myasthenia gravis: FcRn inhibition and beyond	53
Sleep research in 2023: beyond the bare necessities	53
For a dementia diagnosis, clinical acumen must precede biomarkers	53
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	52
Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	52
Thank you to The Lancet Neurology's peer reviewers in 2023	52
NfL is ready for translation into paediatrics	51
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	51
Charles Bell's Renaissance inspiration	50
Laquinimod, Huntington's disease, and disease modification	49
Biomedical research must change as the climate does	49
A brain design for life	48
Carlayne Jackson: leading the American Academy of Neurology	47
Further support for rituximab in relapsing multiple sclerosis	47
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	45
The bases of remembrance	45
Major advances in sleep neurology: 2002–22	44
The cultural history of dementia	44
Neurosurgical lesioning for Tourette syndrome – Authors' reply	43
Geoffrey Manley: TBI guy	43
Advances in amyotrophic lateral sclerosis research in 2022	43
Early atrial fibrillation rhythm control after stroke	43

The optimisation of migraine prevention: an urgent need	42
The complex pathway between amyloid β and cognition: implications for therapy	41
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	41
Changing the landscape of neurological education	41
Essential medicines for neurological disorders: updates, rejections, and the road ahead	41
Digital mobility measures to predict Parkinson's disease	41
Targeting exercise, energy, or both in Friedreich's ataxia	40
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	40
Lifeline	39
Unilateral promise and bilateral caution in focused ultrasound for Parkinson's disease	39
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	38
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	38
Diagnostic and other biomarkers of dementia with Lewy bodies: from research to clinical settings	38
Improving epilepsy diagnosis across the lifespan: approaches and innovations	38
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	37
Sleep matters in anti-LGI1 encephalitis	36
Nanna Brix Finnerup: integrity and openness to alternatives	36
Blue as an orange	36
Video games for people with neurological disorders	35
Acute-onset axonal neuropathy following infection in children with biallelic RCC1 variants: a case series	35
Revisiting levodopa for advanced Parkinson's disease	35
Maria Trojano: advocate for real-world multiple sclerosis studies	35
The prescription of valproate: risk of harm	34
Brain amyloid on the way to dementia prevention	34
Correction to Lancet Neurol 2025; 24: 969–75	34
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	34
Correction to Lancet Neurol 2023; 22: 209–17	34
Correction to Lancet Neurol 2025; 24: 880–92	33
Global burden of meningitis and implications for strategy	33
Time to get serious about the Global Action Plan on dementia	33
Correction to Lancet Neurol 2025; 24: 413–28	33
RAB32 mutation in Parkinson's disease	33
Lifestyle interventions for Parkinson's disease	32
Correction to Lancet Neurol 2024; 23: 344–81	32
Abandon the NAC in α-synuclein	32
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	32
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD	32
Neuroscience research in 2024: advances in blood biomarkers and brain omics	32
Blood pressure reduction and reperfusion therapy	32
Globally advancing neurological education in headache	31
Stroke care and prevention in Europe	31
Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications	30
Nitrous oxide and its neurological harms	30
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	30
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	29
Advances in diagnosis, classification, and management of pain in Parkinson's disease	28
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	27
A neurotransmitter with a fascinating story	27
Addressing neurological burden in the Americas	27
A disease-specific therapy in facioscapulohumeral muscular dystrophy	26
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	26
William Harvey, neurologist?	26
The hidden unity of the mind	25
Treatment of acute subdural haematoma – Authors' reply	25
Innovation in the prevention of neurological diseases	25
Cerebral amyloid angiopathy criteria: the next generation	25
Krithi Irmady	25
Neurology cannot be embedded in non-communicable disease agendas	25
Treatment of asymptomatic carotid stenosis in SPACE-2	24
Transforming amyotrophic lateral sclerosis into a liveable disease	24
Vittorio Marchi's staining	24
With thanks to our peer reviewers in 2022	24
Fetal exposure to antiseizure medications: reassurance and concerns	24
Correction to Lancet Neurol 2019; 18: 748–59	23
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	23
Neuropsychiatry on screen	23
CGRP blockade and cluster headache: another step forward	23
Differential diagnosis of suspected multiple sclerosis: global health considerations	22
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	22
The Stimming Pool: an autistic production	22
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	22
Time to end the stigma of epilepsy	22
Amyotrophic lateral sclerosis: a lesson in translation	22
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	21
Carotid revascularisation for carotid stenosis	21
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	21
Carpal tunnel syndrome: updated evidence and new questions	21
Mar Tintoré, Mar Mediterráneo	20
Chronic effects of inflammation on tauopathies	20
Changing views of disability	20
Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023	20
Cerebral cavernous malformations: to operate or not?	20
Elucidating a new path of CSF transport in the CNS	20
Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease	19
Targeting C9orf72 in people with ALS	19
Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study	19
Takeshi Iwatsubo: a pioneer in Alzheimer's disease research	19
Alzheimer's disease: a history revisited	18
Antibiotic neuromuscular junction myasthenic mimetics	18
Amyloid β, γ-secretase, and familial Alzheimer's disease	18
Rigmor Højland Jensen: the headache warrior	17
Turin as a neuroscience cradle	17
Criteria for a biological definition of neuronal α-synuclein disease—a major conceptual step forward	16
Pragmatic solutions for the global burden of stroke	16
Safety and effectiveness of the Walk ‘n Watch structured, progressive exercise protocol delivered by physical therapists for inpatient stroke rehabilitation in Canada: a phase 3, multisite, pragmatic,	16